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Summary Carboxypeptidase G2, a zinc metalloenzyme isolated from Pseudomonas sp. strain RS-16, which
catalyses the hydrolytic cleavage of reduced and non-reduced folates to pteroates and L-glutamate, has been
linked to a monoclonal antibody (W14A) raised to human chorionic gonadotrophin. The coupling efficiency
and retention of antibody and enzymatic activities are compared for three separate methods of preparing 1:1
conjugates. Preliminary in vitro studies on the cytotoxicity of the free enzyme and the conjugated enzyme
towards JAR choriocarcinoma cells are reported. Despite the limitations of the in vitro model, it could be
demonstrated that a significant proportion of 106 choriocarcinoma cells lost viability when exposed to either
free or conjugated enzyme for 72 hours at concentrations of carboxypeptidase G2 of 1-3 units ml-
' of medium.
Some chemotherapeutic anti-cancer agents function
by entering cells and competing with metabolites
used in DNA synthesis. Certain enzymes, with an
inherently high degree of substrate specificity, may
be capable of depriving a cell of essential
metabolites and may fulfil this function from
outside the cell. Selective delivery to malignant cells
in vivo, by targeting the enzyme conjugated to an
antibody which is directed at a tumour-associated
antigen, at or near the cell surface, offers a
potential means of achieving this.
Folate plays a central role in sustaining cell
replication and cells depend upon a continued
external supply. A major determinant of intra-
cellular folate depletion can be dilution among
cellular progeny. For example, DNA replication in
Friend erythroleukaemia cells becomes compromised
when the intracellular folate (ICF) falls to the
range of 3 x 105 molecules per cell and the cell is
incapable of further replication when the ICF pool
is diminished to less than I x 105 molecules per
cell (Steinberg et al., 1983). The idea of depriving
malignant cells of folate by diminishing extra-
cellular folate is not new. A beneficial effect of
dietary folate depletion in human leukaemia has
been demonstrated (Heinle et al., 1948), and the
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rat is markedly inhibited by folate deficiency (Rosen
et al., 1962).
An enzyme, carboxypeptidase G1, which
catalyses the hydrolytic cleavage of reduced and
non-reduced folates to pteroates and L-glutamate,
was demonstrated to inhibit the growth of L1210
leukaemic cells, amongst others, in vitro (Bertino et
al., 1971). Both methotrexate-sensitive and
methotrexate-resistant cell lines were similarly
affected and this encouraged us to consider the
choriocarcinoma model where methotrexate
resistance may result from amplification of
dihydrofolate reductase activity, as in a number of
other malignancies (Dedhar et al., 1983). Antibody-
directed enzymatic deprivation of folate might be a
valuable adjunct to conventional chemotherapy.
Carboxypeptidase G2 (Sherwood et al., 1985) a
zinc metalloenzyme, isolated from Pseudomonas sp.
strain RS-16, has very similar characteristics to
carboxypeptidase G1, and is a suitable candidate
enzyme for linkage to antibodies against human
chorionic gonadotrophin (hCG), expressed by
syncytiotrophoblastic cells. Preliminary studies in
CC3 choriocarcinoma xenografts in nude mice
(Searle et al., 1981) and radioimmunolocalisation
studies in patients (Goldenberg et al., 1981; Begent
et al., 1985) have already indicated that there is
some selective retention of these antibodies in the
locality of hCG-producing tumours. Auto-
radiography with iodine (125I)-labelled antibodies
suggests the major proportion remains extracellular
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in the xenograft model (Sharma, 1983). The
preparation of anti-hCG-carboxypeptidase G2
conjugates has been undertaken to establish
suitable methods to link the proteins without
unacceptable losses of antibody or enzyme activity.
Preliminary in vitro studies with JAR chorio-
carcinoma cells have been initiated in order to gain
some insight into the requirements of local
concentration, time of retention, and enzymatic
activity required to produce a cytotoxic effect.
Three methods were used in this study to couple
carboxypeptidase G2 to anti-human chorionic
gonadotrophin antibody. All were based on hetero-
functional reagents which react with an amino
group on one protein and a thiol residue on the
second. A variety of coupling methods was chosen
to enable the in vivo stability of the different bonds
to be studied.
Carboxypeptidase G2 does not possess any free
thiol groups (Minton et al., 1984) and was not
considered suitable for the introduction of such
residues because of loss of activity under the
reaction conditions used for the reduction of 2-
pyridyldisulphide groups. This limitation did not
apply to the antibody, and hence it was this
molecule which was thiolated. The reaction of the
heterobifunctional reagents with amino groups
occurs at approximately neutral pH and caused no
major difficulties with the enzyme.
The heterobifunctional reagents used were N-
succinimidyl-3-(2-pyridyldithio)-propionate (SPDP)
which generates a disulphide bridge between the
two protein molecules; the N-hydroxysuccinimide
ester of iodoacetic acid (NHIA) which forms a
thioether bond between the protein molecules and
N-maleimidobenzoyl succinimide ester (MBS), the
active maleimide bond of which forms a thioether
bond with a thiol group on one protein, with the
active ester acylating an amino group on the second
protein.
Materials and methods
Materials
Chemicals N-Succinimidyl-3-(2-pyridyldithio) pro-
pionate (SPDP) was purchased from Pharmacia
Ltd., Milton Keynes, UK; N-hydroxysuccinimide
and N,N-dicyclohexylcarbodiimide were purchased
from Aldrich Ltd., Gillingham, Dorset, UK; N-
maleimidobenzoyl succinimide ester (MBS) and
5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) were
purchased from Sigma Ltd, Poole, Dorset, UK; 1,4-
dioxan (which was applied to a column of
aluminium oxide before use), iodoacetic acid and
all other chemicals, which were of 'Analar' grade,
were purchased from B.D.H. Ltd., Poole, Dorset,
UK.
Biological materials Carboxypeptidase G2
(330Umg-1) was produced by the Microbial
Technology Laboratory following a previously
described protocol (Sherwood et al., 1985).
Antihuman chorionic gonadotrophin, anti-hCG
W14A, an IgG1 mouse monoclonal antibody was
prepared from ascites as reported previously (Searle
et al., 1984). JAR choriocarcinoma cells were a gift
from Professor R. Pattillo.
Buffers 0.05M sodium phosphate buffer, pH 7.5
containing 0.15 M NaCl; 0.1 M sodium acetate,
pH 7.0, containing 0.15 M NaCl; 0.1 M Tris-HCl,
pH 7.3, containing 0.2mm ZnCl2; phosphate-
buffered saline (PBS): NaCl 0.8%, w/v, KC10.02%,
w/v, Na2HPO4 0.13%, w/v, KH2PO4 0.02%, w/v;
pH 7.4.
Chromatographic materials Bio-Gel P30 was
purchased from Bio-Rad Ltd, Watford, Herts, UK,
Sephacryl S300 Superfine and Sephadex G25M
prepacked (PD 10) columns were purchased from
Pharmacia Ltd, Milton Keynes, UK, and Ultrogel
AcA 34 was purchased from LKB Ltd, Croydon,
UK.
Media for cell culture DMEM with 20mM
HEPES buffer, supplemented with 10% foetal calf
serum (Flow Laboratories), penicillin 100UmlP1
(Glaxo), streptomycin sulphate 100Mgml-1, (Evans
Medical Ltd, Middlesex) and L-glutamine 2mm
(Gibco). DMEM contains 4.0mg 1- of folate.
Folate-depleted medium, was Medium 199 with
Earle's salts supplemented as above and, contains
0.01 mgI-P of folate. The folate content of the
foetal calf serum batch was 9.3MgI1.
Methods
Determination of biological activities Carboxy-
peptidase G2 activity was measured spectrophoto-
metrically at 37°C in tris-HCl buffer with 0.06mM
methotrexate as substrate in a total volume of 1 ml.
The reaction was started by the addition of enzyme
and followed by the decrease in absorbance at
320nm (Hughes et al., 1982; McCullough et al.,
1971).
Anti-hCG activity relative to starting material
was measured as described previously (Searle et al.,
1984). Antiserum dilution curves were set up as
follows: each tube contained a mixture of
phosphate buffer (200Ml), antibody or conjugate at
different dilutions in 1/400 normal mouse serum in
phosphate buffer (50pl), Il25-hCG (50p1 of stock
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achieve 60-70,000c.p.m.). Reaction mixtures were
incubated for 16h at room temperature and then
rabbit antimouse immunoglobulin (50 1l) added to
a final dilution of 1/280 together with 10%
polyethylene glycol 6000 (501I). The whole was
incubated for a further 2h at room temperature
and then filtered and counted (Searle et al., 1984).
Thiolation ofanti-hCG One hundred pl of a stock
solution of SPDP reagent (2.08mgml- 1) in ethanol
were added, with stirring, to a solution of anti-hCG
(1Omg) in phosphate buffer (3.5ml). After stirring
at room temperature for 30min, the mixture was
applied to a column ofBioGel P30 (15mm x 240mm)
pre-equilibrated with acetate buffer and eluted
with the same buffer. Immunoglobulin-containing
fractions were tested (Carlsson et al., 1978) to
determine the degree of incorporation of 2-
pyridyldisulphide residues.
Dithiothreitol (3.9mg) was added to the
substituted immunoglobulin solution (5.1 ml). After
stirring for 20min at room temperature, the
mixture was applied to a column of BioGel P30
(15mm x 240mm) pre-equilibrated with phosphate
buffer, and eluted (1.75ml fractions) with the same
buffer. Fractions containing anti-hCG (7ml) were
pooled.
Preparation of anti-hCG-carboxypeptidase G2
conjugate using NHIA One hundred and twenty-
threepl of a stock solution of NHIA (12.5mgml 1)
(Rector et al., 1978) in dimethylformamide were
added with stirring, in portions, to a solution of
carboxypeptidase G2 (11 mg) in phosphate buffer
(2.5nml). After stirring for 40min at room
temperature, the mixture was applied to a column
of Bio-Rad P30 (15mmx240mm), pre-equilibrated
with phosphate buffer, and eluted (1.75ml
fractions) with the same buffer. The carboxy-
peptidase G2 fraction (7ml) was tested spectro-
photometrically to confirm the introduction of
iodoacetyl groups (Thorpe et al., 1984).
The iodoacetylated carboxypeptidase G2 was
mixed with thiolated anti-hCG prepared as above,
and the mixture concentrated to 2.5ml by ultra-
filtration and allowed to react for 60h at room
temperature. Anti-hCG-carboxypeptidase G2
conjugate was purified by column chromatography
on Sephacryl S300 Superfine (26mm x 650mm),
pre-equilibrated and eluted with phosphate buffer.
Fractions (2.75ml) containing antibody and enzyme
activity were pooled from several preparations to
give a total of 160ml, concentrated 10-fold by
ultrafiltration and stored at -70°C.
Preparation of anti-hCG-carboxypeptidase G2
comjugate using SPDP Fifty ul of a stock solution
of SPDP reagent (2.1 mgml-1) in ethanol were
added with stirring, to a solution of carboxy-
peptidase G2 (5.5mg) in phosphate buffer (2.4ml).
After stirring for 40min at room temperature, the
mixture was applied to a Sephadex G25M (PD1O)
column, pre-equilibrated and eluted with phosphate
buffer. An aliquot was retained for the
determination of 2-pyridyldisulphide residue-
incorporation as before. Fractions (0.5ml) were
collected and assayed for enzyme activity. The peak
fractions (3.5ml) were mixed with thiolated anti-
hCG (5mg, 3.5ml), the mixture concentrated to
2.5ml by ultrafiltration, and allowed to react for
60h at 4°C. Anti-hCG-carboxypeptidase G2
conjugate was purified by chromatography on a
column of Ultrogel AcA34 (22mmx900mm), pre-
equilibrated and eluted with phosphate buffer.
Fractions (2ml) were collected and assayed as
before.
Preparation of anti-hCG-carboxypeptidase G2
conjugate using MBS Fifty pl of a stock solution
of MBS (4.2mgml-1 in tetrahydrofuran) were
added with stirring to a solution of carboxy-
peptidase G2 (5.5mg) in phosphate buffer (2.4ml).
After stirring for 40min, the mixture was applied to
a Sephadex G25M (PD10) column pre-equilibrated
and eluted with phosphate buffer. Fractions (0.5ml)
were collected and assayed for enzyme activity.
Peak fractions (3.5ml) were pooled and an aliquot
retained for the determination of MBS
incorporation by measuring the decrease of the
thiol content on its addition to mercaptoethanol
(100nmol) using Ellman's reagent (DTNB) (Sedlack
& Lindsay, 1968). The pooled, activated enzyme
was mixed with thiolated anti-hCG, (5mg, 3.5ml)
the mixture concentrated to 2.5ml by ultrafiltration
and allowed to react for 60h at 4°C. Anti-hCG-
carboxypeptidase G2 was isolated by chromato-
graphy on a column of Ultrogel AcA 34
(22mmx900mm) pre-equilibrated and eluted with
PBS. Fractions (2ml) were collected and assayed as
before.
Growth inhibition of JAR choriocarcinoma cells by
carboxypeptidase G2 Cells were trypsinized (0.5%
trypsin and 0.02% EDTA in saline) from stock
flasks and seeded at 1 x 105 cells/well in 1 ml
DMEM+10% foetal calf serum per well for
controls and 1ml 199+10% foetal calf serum for
folate-depleted controls. After 24h, viable cells in
triplicate wells were estimated by trypsinization of
the adherent cells and counting with a haemo-
cytometer using trypan blue uptake. The stock
media were renewed at 24h intervals in further
control wells for 4 days, while experimental
triplicate wells were exposed to medium 199380 F. SEARLE et al.
containing 1.5, 3.0 and 15.0 units of carboxy-
peptidase G2 ml-1 respectively, these media also
being renewed at 24h intervals. Cell counts of
representative triplicate wells were obtained as
above at each change of medium.
Growth inhibition ofJAR choriocarcinoma cells by a
conjugate of anti-hCG and carboxypeptidase
G2 Similar experiments to those described above
were set up whereby the growth of the cells in
medium 199+10% foetal calf serum was compared
with medium 199+10% foetal calf serum
containing conjugate with enzyme activity assessed
at 0.86 and 1.14Uml- 1
Results
Conjugation ofproteins
The levels of incorporation into protein of the
heterobifunctional reagents employed are listed in
Table I. The reagents were reacted with the proteins
in a molar excess between 5 and 40-fold. At these
concentrations the loss of enzyme activity averaged
20%.
Typically, a starting enzyme preparation,
330Umg-1 of protein, yielded a final product with
a molecular weight consistent with components
150,000 for antibody+83,000 for enzyme,
equivalent to an enzyme specific activity of
210Umg-1 of enzyme protein. No significant loss
of antibody activity was encountered, but rigorous
interpretation was hampered by the possible
presence of some free anti-hCG in the preparation
(see later). The level of incorporation of MBS into
carboxypeptidase G2 was < 1 molmol- 1 of
carboxypeptidase on average, but this was not
considered a disadvantage since there was
approximately a 2-fold molar excess of carboxy-
peptidase G2 present in the reaction mixtures.
Purification ofconjugates
Purification of the conjugates by gel filtration on
either Ultrogel AcA 34 or Sephacryl S300 gave
essentially similar results. The elution profile of
NHIA-linked conjugate from Sephacryl S300, and
SPDP-linked conjugate from Ultrogel AcA 34
columns are illustrated in Figures 1 and 2
respectively. The only significant difference between
the coupling methods was the formation of high
molecular weight material, comprised of carboxy-
peptidase G2 polymers, when SPDP was used as
the coupling method. Such polymers probably arise
through the decay of 2 pyridyl disulphide residues
to the thiol form, since carboxypeptidase G2 lacks
free thiol groups. The elution profile of MBS-linked
conjugate from Ultrogel AcA 34 is not illustrated
but closely resembles that of the NHIA-linked
material.
The elution profiles show that the conjugate was
eluted at a similar position to the calibration
protein catalase, indicating a molecular weight of
approximately 230,000 daltons, which was very
close to that predicted for a 1: 1 conjugate of anti-
hCG and carboxypeptidase G2. The conjugate was
well separated from free carboxypeptidase G2, but
the free anti-hCG peak overlapped to some extent
and the pooled conjugate fractions may have
contained some free anti-hCG.
The approximate yields of the reactions, with
respect to antibody, since carboxypeptidase G2 was
present in molar excess, estimated by measurement
of the peak areas of free and conjugated antibody
are presented in Table II. These values indicated
that the thio-ether bond-forming reactions gave
greater yields than the disulphide bridge-forming
reactions.
Inhibition ofgrowth ofJAR choriocarcinoma cells
in vitro byfolate deprivation
The control JAR choriocarcinoma cells in
DMEN+10% foetal calf serum replicated for the
first three days of the experiment but thereafter
ceased to adhere satisfactorily, invalidating
investigations beyond this time. The cells which
ceased to adhere during the first 72h in test wells
were no longer viable as judged by their incapacity
to re-grow on re-seeding in control media.
Table I Incorporation of active residues into CPG2 and anti-hCG using heterobifunctional reagents
Molar excess No. ofmol. active % initial activity % initial activity
Protein Reagent ofreagent residues incorporated loss on activation loss on coupling
CPG2 MBS 10-fold 0.66 19.4 10.9
CPG2 SPDP 5-fold 5a 24.4 17.6
CPG2 NHIA 40-fold 5 19.4 14.0
anti-hCG SPDP 10-fold 2b nm 1oc
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Figure 1 Chromatographic separation of the anti-human chorionic gonadotrophin thioether linked to
carboxypeptidase G2 conjugate on Sephacryl S300. (0) absorbance280; (A) enzyme activity; (0) antibody
activity (B/T% vs dilutions of 32768 ofeach fraction).
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Figure 2 Chromatographic separation of the anti-human chorionic gonadotrophin disulphide linked to
carboxypeptidase G2 conjugate on Ultrogel AcA 34. (0) antibody activity; (0) enzyme activity.
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Table II Coupling efficiency of conjugation reactions
with respect to antibody
% antibody incorporated
Coupling method (as 1:1 conjugate)
SPDP 27.9
MBS 42.7
NHIA 35-40
Confluence could be delayed by seeding at 0.6 x 104
cells/well, but enzyme potency was then less readily
demonstrable.
Growth was inhibited in medium 199+10%
foetal calf serum without enzyme in comparison to
the DMEM control, and further inhibited by the
presence of 3 units of free carboxypeptidase
G2 10-5 cells. Cytotoxicity was confirmed at 15
units of enzume 10-5 cells, no viable cells were
recovered after 2 days (TableIII). For one anti-
hCG-carboxypeptidase G2 conjugate (NHIA-
linked), a measurable effect was detected at -1
unit of enzyme 10-5 cells in medium 199+10%
foetal calf serum (Table III). Comparable results
were obtained by maintaining the cells in
unchanged medium over 72h and adding small
volumes ofconcentrated enzyme daily.
Table IlI (a) Comparative numbers (x 10-5) of viable
JAR choriocarcinoma cells in DMEM, medium 199 and
medium 199 containing carboxypeptidase G2
Medium Day 0 Day I Day 2 Day 3
DMEM 0.7 1.05 1.55 2.25
199 0.7 0.6 1.0 1.45
199+ 15U 0.7 0.3 Undetectable Undetectable
199+3U 0.7 0.65 0.45 0.18
199+ 1.5U 0.7 0.6 0.73 1.2
Table III (b) Comparative numbers (x 10-) of viable
JAR choriocarcinoma cells in medium 199 and medium
199 containing anti-human chorionic gonadotrophin-
carboxypeptidase G2 conjugate
Medium Day 0 Day 1 Day 2 Day 3
199 1 1.74 2.2 2.34
199+0.86U 1 1.85 2.1 0.49
199+ 1.14U 1 1.3 1.61 0.36
U =Units of enzyme activity per well.
Standard deviations ranged from +0.3 to +0.6.
Discussion
In order for the conjugate between anti-hCG
(W14A) and carboxypeptidase G2 to function as a
potential anti-neoplastic agent, it must express both
immunological and enzymatic activity. The newly-
created linkage must not be susceptible to speedier
cleavage in vivo than the general metabolic
breakdown to which the proteins themselves would
be exposed prior to reaching the tumour cell. The
properties of cross-linking agents have been
reviewed extensively (Means & Feeney, 1971;
Weetall & Cooney, 1981; Ghose et al., 1983; Han,
1984) in relation to the sites of modification of the
proteins. One of the most common approaches to
conjugate preparation has been to enrich one
component with thiol groups. Many antibody
conjugates, particularly immunotoxins, have been
coupled using a direct disulphide bridge but
opinions differ as to the stability of this linkage in
vivo. For example, it has been concluded from
experiments on the immunosuppressive activity of
abrin conjugates in mice (Thorpe et al., 1982) that
the disulphide bond, when used to couple two
unrelated proteins, is not reinforced by covalent
forces and may be particularly susceptible to
cleavage in vivo. Similarly, instability of a
disulphide-linked conjugate between anti-transferrin
antibody and ricin A chain may have been
encountered in mice (Trowbridge et al., 1981). In
contrast, data have been presented on the depletion
of 6 neoplastic BCL cells in mice, with a ricin A
disulphide-linked antibody, which suggests requisite
stability is maintained in this system (Vitetta et al.,
1982).
It is difficult to predict the in vivo stability of
conjugates with different protein components. Both
disulphide-bridged and thio-ether-linked conjugates
of anti-hCG and carboxypeptidase G2 have been
prepared and all three coupling methods tested
produced satisfactory conjugates in that antibody
and enzyme activities were retained. Their in vivo
stabilities are currently under investigation.
The studies with JAR cells reported here suggest
that carboxypeptidase G2, even when conjugated to
anti-hCG antibody, is cytotoxic to choriocarcinoma
cells. Actual levels of administered enzyme needed
to destroy the cells can vary in different cell lines
(for example, 30 units 10- 5 BeWo choriocarcinoma
cells) and are much higher than were anticipated by
analogy with earlier work (Bertino et al., 1971).
The enzyme remains active in the medium as
estimated by spectrophotometric assays of diluted
medium in buffer, but this does not eliminate
rigorously the possibility of some inhibition of
enzyme in the cell medium. In dealing with anANTITUMOUR ENZYME-ANTIBODY CONJUGATES 383
antibody to a secreted antigen such as human
chorionic gonadotrophin, the saturation of
antibody sites at the cell surface need not be a
limiting factor, since accumulation in vivo would
depend rather on the concentration gradient of
soluble antigen. Extrapolation to the in vivo model
depends upon too many variables to be certain of
an in vivo response from these measurements.
However, the in vitro model can be used to answer
specific questions. For example, further work is
necessary to see how far cells which have been
exposed to the enzyme can be rescued by
withdrawing the enzyme and administering folate,
since this would simulate more correctly the
potential situation in vivo. It is premature to draw
conclusions about the relative potency of the
enzyme and its conjugate from these results. The
model may be complicated by the release of folate
from damaged cells into the medium. Provided the
folate remains in its intracellular pentaglutamate
form, it will be unlikely to re-enter viable cells
through monoglutamate transport pathways.
However, competition may develop between the
released pentaglutamate and monoglutamate
substrate in the medium such that, at low levels of
the enzyme, dose responses in the presence of dying
cells will be difficult to interpret rigorously. So far
the efficacy of the enzyme has been demonstrable
over a rather narrow range of cell numbers, in the
plates used, which had to be balanced against the
relatively short time before the cells reached
confluence: it is possible that the cell doubling time
and the number of damaged cells releasing folate
are critical experimental parameters to demonstrate
the growth inhibition. So far it has not been
possible for us to remove the dependence of the
cells on 10% foetal calf serum in these media and
the model may be complicated by potential
interactions of folate with folate-binding protein in
the serum. It had been hoped that the cells could be
induced to grow satisfactorily in medium 199 with
known levels of folate added, to study the effect of
the enzyme more extensively. Despite the
limitations of the model the inhibition of the cell
growth by carboxypeptidase G2 in the free and
conjugated form is significant and consistent with
the postulate that the inhibition is due to folate
depletion. A significant proportion of the cells
appear to lose viability at concentrations of enzyme
as low as 3Uml-1. Preliminary data (not shown)
on the uptake of tritiated thymidine or tritiated
leucine by JAR cells exposed to carboxypeptidase
G2 are in general accordance with these results but
remain to be evaluated fully. The incorporation of
both thymidine and leucine can theoretically be
distorted by folate depletion (Taheri et al., 1981;
Grzelakowska-Sztabert, 1983) and are therefore
unsatisfactory direct measures of cell viability in
this model.
How far are the in vitro observations an
indication of the potential of the anti-hCG-
carboxypeptidase G2 conjugates for destroying
choriocarcinoma cells in vivo? Normal serum folates
in the human consist of a fairly constant level of
10-formyl-tetrahydrofolate maintained by homeo-
static mechanisms and variable levels of 5-
methyl-tetrahydrofolate as a storage form (Halpern
et al., 1977). In attempts to deplete folate artificially
there will be little help from normal catabolism.
The total folate requirement of a 70kg subject is
maintained by an intake of only 50pg daily
(Halpern et al., 1977). In conditions where the total
folate pool is depleted, as in some malignancies,
there is a shift whereby 10-formyl-folates are
preferentially formed from folic acid. In some adult
leukaemic patients there are increased levels of 10-
formyl-tetrahydrofolate, although both total folate
and 5-methyl-tetrahydrofolate levels are signifi-
cantly decreased.
Carboxypeptidase G2, in the locality of the
tumour, will have to encounter a background level
of interstitial folate and the serum folate pool with
which the interstitial fluid is in equilibrium. From
figures for serum folate levels in normal and
leukaemic subjects (Ratanasthian et al., 1974), a
reasonable estimate for total serum folates would
be I0ngml-1, presumably in equilibrium with
interstitial content. Serum folate levels should,
however, be considerably reduced through the
activity of circulating enzyme-antibody conjugate
during treatment. Had we been able to demonstrate
JAR cell cytotoxicity in DMEM+10% foetal calf
serum (i.e. 4,000ngml -1 folate) we would be
confident that the enzyme is sufficiently potent to
attack small residual deposits of choriocarcinoma
cells in vivo as a conjugated single agent. The 199
medium+10% foetal calf serum (1Ingml- folate)
is closer to the estimated serum background level,
but to maintain a concentration of 15Uml-1 of
enzyme in the locality of the tumour in vivo could
present difficulties. A great deal will depend on the
distribution and stability of the enzyme conjugate in
vivo which is the subject of current investigations.
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